JPMorgan upgrades Genmab to Overweight, lifts price target
Alpha Vantage · Investing.com Nigeria · · AI-summarised by FinFlash
JPMorgan upgraded Genmab A/S to Overweight from Neutral and raised its price target, anticipating positive results from the first-line peto interim head and neck overall response rate Phase III readout in November. The firm lifted its peak sales forecast for peto to $5 billion, citing higher market share assumptions and strong Phase II data.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.